88899-55-2

• 常用中文名：巴佛洛霉素A1
• 常用英文名：Bafilomycin A1
• CAS号：88899-55-2
• 分子式：C₃₅H₅₈O₉
• 分子量：622.830
• 相关类别： 原料药 人工合成抗感染类药 抗真菌类药
• 发布时间：2018-06-11 08:01:22
• 更新时间：2024-01-03 16:15:12
• Bafilomycin A1,一种从链霉菌属物种中分离的大环内酯类抗生素,是特异的 vacuolar-type H+ ATPase 抑制剂。

名称

• 中文名: 巴佛洛霉素A1
• 英文名: bafilomycin A1
• 中文别名: 维生素 D2
• 英文别名: (5R)-2,4-Dideoxy-1-C-{(2S,3R,4S)-3-hydroxy-4-[(2R,3S,4E,6E,9S,10S,11R,12E,14Z)-10-hydroxy-3,15-dimethoxy-7,9,11,13-tetramethyl-16-oxooxacyclohexadeca-4,6,12,14-tetraen-2-yl]pentan-2-yl}-5-isopropyl-4-methyl-α-D-threo-pentopyranose; α-D-threo-Pentopyranose, 2,4-dideoxy-1-C-[(1S,2R,3S)-2-hydroxy-3-[(2R,3S,4E,6E,9S,10S,11R,12E,14Z)-10-hydroxy-3,15-dimethoxy-7,9,11,13-tetramethyl-16-oxooxacyclohexadeca-4,6,12,14-tetraen-2-yl]-1-methylbutyl]-4-methyl-5-C-(1-methylethyl)-, (5R)-; 21-O-de(3-carboxy-1-oxo-2-propenyl)-2-demethyl-2-methoxy-24-methyl-hygrolidin; bafilomycin A; MFCD06795130; Oxacyclohexadeca-3,5,11,13-tetraen-2-one, 8-hydroxy-16-[(1S,2R,3S)-2-hydroxy-1-methyl-3-[(2R,4R,5S,6R)-tetrahydro-2,4-dihydroxy-5-methyl-6-(1-methylethyl)-2H-pyran-2-yl]butyl]-3,15-dimethoxy-5,7,9,11-; α-D-threo-Pentopyranose, 2,4-dideoxy-1-C-[(1S,2R,3S)-2-hydroxy-3-[(3S,4Z,6Z,9S,10S,11R,12Z,14E)-10-hydroxy-3,15-dimethoxy-7,9,11,13-tetramethyl-16-oxooxacyclohexadeca-4,6,12,14-tetraen-2-yl]-1-met hylbutyl]-4-methyl-5-C-(1-methylethyl)-, (5R)-; (5R)-2,4-Dideoxy-1-C-{(2S,3R,4S)-3-hydroxy-4-[(2R,3S,4E,6E,9S,10S,11R,12E,14Z)-10-hydroxy-3,15-dimethoxy-7,9,11,13-tetramethyl-16-oxooxacyclohexadeca-4,6,12,14-tetraen-2-yl]-2-pentanyl}-5-isopropyl-4- ;methyl-α-D-threo-pentopyranose; BafilomycinA1fromStreptomycesgriseus; (5R)-2,4-Dideoxy-1-C-{(2S,3R,4S)-3-hydroxy-4-[(3S,4Z,6Z,9S,10S,11R,12Z,14E)-10-hydroxy-3,15-dimethoxy-7,9,11,13-tetramethyl-16-oxooxacyclohexadeca-4,6,12,14-tetraen-2-yl]-2-pentanyl}-5-isopropyl-4-met ;hyl-α-D-threo-pentopyranose; BAFILOMYCIN A1; bafilomycin; tetramethyl-, (3Z,5E,7R,8S,9S,11E,13E,15S,16R)-; (3Z,5E,7R,8S,9S,11E,13E,15S,16R)-8-Hydroxy-16-[(1S,2R,3S)-2-hydroxy-1-Methyl-3-[(2R,4R,5S,6R)-tetrahydro-2,4-dihydroxy-5-Methyl-6-(1-Methylethyl)-2H-pyran-2-yl]butyl]-3,15-diMethoxy-5,7,9,11-tetraMethyloxacyclohexadeca-3,5,11,13-tetraen-2-o; (3Z,5E,7R,8S,9S,11E,13E,15S,16R)-8-Hydroxy-16-((1S,2R,3S)-2-hydroxy-1-methyl-3-((2R,4R,5S,6R)-tetrahydro-2,4-dihydroxy-5; Bafilomycin A1 from Streptomycesgriseus,10 ug; α-D-threo-Pentopyranose, 2,4-dideoxy-1-C-[(1S,2R,3S)-2-hydroxy-3-[(2R,3S,4E,6E,9S,10S,11R,12E,14Z)-10-hydroxy-3,15-dimethoxy-7,9,11,13-tetramethyl-16-oxooxacyclohexadeca-4,6,12,14-tetraen-2-yl]-1- methylbutyl]-4-methyl-5-C-(1-methylethyl)-, (5R)-

物化性质

• 密度: 1.1±0.1 g/cm3
• 沸点: 770.1±60.0 °C at 760 mmHg
• 分子式: C₃₅H₅₈O₉
• 分子量: 622.830
• 闪点: 232.2±26.4 °C
• 精确质量: 622.408081
• PSA: 134.91000
• LogP: 3.88
• 蒸汽压: 0.0±6.0 mmHg at 25°C
• 折射率: 1.535
• 储存条件:

  2-8°C冷藏

• 分子结构:

  1、 摩尔折射率：171.94

  2、 摩尔体积（m³/mol）：552.3

  3、 等张比容(90.2K)：1438.8

  4、 表面张力(dyne/cm)：46.0

  5、 极化率(10-24cm³)：68.16

• 计算化学:

  1、 疏水参数计算参考值（XlogP）：6

  2、 氢键供体数量：4

  3、 氢键受体数量：9

  4、 可旋转化学键数量：7

  5、 互变异构体数量：

  6、 拓扑分子极性表面积（TPSA）：135

  7、 重原子数量：44

  8、 表面电荷：0

  9、 复杂度：1060

  10、同位素原子数量：0

  11、确定原子立构中心数量：12

  12、不确定原子立构中心数量：0

  13、确定化学键立构中心数量：4

  14、不确定化学键立构中心数量：0

  15、共价键单元数量：1

生物活性

• 描述: Bafilomycin A1,一种从链霉菌属物种中分离的大环内酯类抗生素,是特异的 vacuolar-type H+ ATPase 抑制剂。
• 相关类别:
  信号通路 >> 跨膜转运 >> 质子泵
  研究领域 >> 癌症
  研究领域 >> 感染
• 靶点:

  H+ ATPase[1]

• 体外研究: 低浓度(1nM)的巴弗洛霉素A1有效且特异性地抑制并杀死小儿B细胞急性淋巴细胞白血病细胞。它针对自噬途径的早期和晚期,线粒体并诱导不依赖caspase的细胞凋亡。巴弗洛霉素A1诱导Beclin 1与Bcl-2的结合,进一步抑制自噬并促进凋亡细胞死亡[1]。 BEL-7402肝细胞癌和HO-8910卵巢癌细胞系的生长受到阻滞,并且巴弗洛霉素A1抑制了转移潜能。透射电子显微镜和capsase-3和-9的测定表明,巴弗洛霉素A1诱导细胞凋亡[2]。巴弗洛霉素A1剂量依赖性地抑制多种培养细胞的生长,包括金仓鼠胚胎和NIH-3T3成纤维细胞,无论它们是否被转化,以及PC12和HeLa细胞。巴弗洛霉素A1抑制细胞生长的IC50范围为10至50 nM [3]。
• 体内研究: 用低剂量巴弗洛霉素A1(0.1mg/kg)慢性治疗略微抑制肿瘤体积,但最终肿瘤体积与对照没有显着差异。然而,与对照组相比,高剂量巴弗洛霉素A1(1 mg/kg)的慢性治疗在21天后显着抑制肿瘤生长[4]。
• 细胞实验: 使用0.05％胰蛋白酶收获细胞并悬浮于含有10％FCS的培养基中，并将200μL悬浮液加入96孔板的每个孔中。将细胞培养20小时以进行粘附。将巴弗洛霉素A1以200,400和800nM的终浓度加入孔中，一式三份。在24,48和72小时，向细胞中加入20μlWST-1。在37℃下孵育4小时后，读取平板以使用分光光度计[2]确定435nm处的光密度（OD）和675nm参比。
• 动物实验: 小鼠：将携带肿瘤的小鼠随机分成三个实验组：低剂量巴弗洛霉素A1（0.1mg / kg每天）治疗组（n = 5），高剂量巴弗洛霉素A1（1mg / kg每天） - 治疗组（n = 5）和对照组（n = 5）。测量肿瘤大小并计算肿瘤体积倍增时间[2]。
• 参考文献:

  [1]. Yuan N, et al. Bafilomycin A1 targets both autophagy and apoptosis pathways in pediatric B-cell acute lymphoblastic leukemia. Haematologica. 2015 Mar;100(3):345-56.

  [2]. Lu X, et al. Bafilomycin A1 inhibits the growth and metastatic potential of the BEL-7402 liver cancer and HO-8910 ovarian cancer cell lines and induces alterations in their microRNA expression. Exp Ther Med. 2015 Nov;10(5):1829-1834.

  [3]. Ohkuma S, et al. Inhibition of cell growth by bafilomycin A1, a selective inhibitor of vacuolar H(+)-ATPase. In Vitro Cell Dev Biol Anim. 1993 Nov;29A(11):862-6.

  [4]. Ohta T, et al. Bafilomycin A1 induces apoptosis in the human pancreatic cancer cell line Capan-1. J Pathol. 1998 Jul;185(3):324-30.

MSDS

Name: Bafilomycin A1 Material Safety Data Sheet Synonym: CAS: 88899-55-2 Section 1 - Chemical Product MSDS Name:Bafilomycin A1 Material Safety Data Sheet Synonym: Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS CAS# Chemical Name content EINECS# 88899-55-2 Bafilomycin A1 unlisted Hazard Symbols: XI Risk Phrases: 36/37/38 Section 3 - HAZARDS IDENTIFICATION EMERGENCY OVERVIEW Irritating to eyes, respiratory system and skin. Potential Health Effects Eye: Causes eye irritation. Skin: Causes skin irritation. Ingestion: May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated. Inhalation: Causes respiratory tract irritation. The toxicological properties of this substance have not been fully investigated. Chronic: Not available. Section 4 - FIRST AID MEASURES Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid. Skin: Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Ingestion: Get medical aid. Wash mouth out with water. Inhalation: Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid. Notes to Physician: Section 5 - FIRE FIGHTING MEASURES General Information: As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. Extinguishing Media: Use extinguishing media most appropriate for the surrounding fire. Section 6 - ACCIDENTAL RELEASE MEASURES General Information: Use proper personal protective equipment as indicated in Section 8. Spills/Leaks: Vacuum or sweep up material and place into a suitable disposal container. Section 7 - HANDLING and STORAGE Handling: Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes. Storage: Store in a tightly closed container. Deep freeze (below -20C). Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION Engineering Controls: Use adequate ventilation to keep airborne concentrations low. Exposure Limits CAS# 88899-55-2: Personal Protective Equipment Eyes: Not available. Skin: Wear appropriate protective gloves to prevent skin exposure. Clothing: Wear appropriate protective clothing to prevent skin exposure. Respirators: Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced. Section 9 - PHYSICAL AND CHEMICAL PROPERTIES Physical State: Powder Color: white to off-white Odor: Not available. pH: Not available. Vapor Pressure: Not available. Viscosity: Not available. Boiling Point: Not available. Freezing/Melting Point: Not available. Autoignition Temperature: Not available. Flash Point: Not available. Explosion Limits, lower: Not available. Explosion Limits, upper: Not available. Decomposition Temperature: Solubility in water: soluble in ethanol Specific Gravity/Density: Molecular Formula: Molecular Weight: 622.80 Section 10 - STABILITY AND REACTIVITY Chemical Stability: Stable under normal temperatures and pressures. Conditions to Avoid: Incompatible materials. Incompatibilities with Other Materials: Strong oxidizing agents. Hazardous Decomposition Products: Carbon monoxide, carbon dioxide. Hazardous Polymerization: Will not occur. Section 11 - TOXICOLOGICAL INFORMATION RTECS#: CAS# 88899-55-2 unlisted. LD50/LC50: Not available. Carcinogenicity: Bafilomycin A1 - Not listed by ACGIH, IARC, or NTP. Section 12 - ECOLOGICAL INFORMATION Section 13 - DISPOSAL CONSIDERATIONS Dispose of in a manner consistent with federal, state, and local regulations. Section 14 - TRANSPORT INFORMATION IATA No information available. IMO No information available. RID/ADR No information available. Section 15 - REGULATORY INFORMATION European/International Regulations European Labeling in Accordance with EC Directives Hazard Symbols: XI Risk Phrases: R 36/37/38 Irritating to eyes, respiratory system and skin. Safety Phrases: S 26 In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S 37/39 Wear suitable gloves and eye/face protection. WGK (Water Danger/Protection) CAS# 88899-55-2: No information available. Canada None of the chemicals in this product are listed on the DSL/NDSL list. CAS# 88899-55-2 is not listed on Canada's Ingredient Disclosure List. US FEDERAL TSCA CAS# 88899-55-2 is not listed on the TSCA inventory. It is for research and development use only. SECTION 16 - ADDITIONAL INFORMATION N/A

安全

• 个人防护装备: dust mask type N95 (US);Eyeshields;Gloves
• 危害码 (欧洲): Xi: Irritant;
• 风险声明 (欧洲): R36/37/38
• 安全声明 (欧洲): 26-36
• 危险品运输编码: UN 3172
• WGK德国: 3
• 包装等级: III
• 危险类别: 6.1(b)

合成路线

上下游产品

上游产品  4
243468-81-7 381246-92-0 381247-15-0 381246-91-9
下游产品  0